-
Oct 31, 2024 | 
caixinglobal.com | Hua Ang |Huang Yanhao |Kelly Wang
Personalised advertising and content, advertising and content measurement, audience research and services developmentStore and/or access information on a deviceYou can choose how your personal data is used.
-
Oct 31, 2024 | 
caixinglobal.com | Hua Ang |Huang Yanhao |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
AstraZeneca PLC’s China president is under investigation by the Chinese authorities, the company disclosed this week, as the British pharma giant continues to grapple with allegations involving medical insurance fraud and the importing of unapproved drugs in the country.
-
Oct 23, 2024 | 
caixinglobal.com | Hua Ang |Wang Xintong
QuantumPharm Inc., a Chinese AI-driven pharmaceutical company, recently became the first firm in its sector to go public in Hong Kong under new IPO regulations encouraging tech company listings. The company's IPO, backed by Tencent Holdings Ltd., marks a shift in investor sentiment toward AI pharmaceuticals, albeit cautiously, as the industry hasn't yet produced profitable products or market-ready drugs.
-
Oct 23, 2024 | 
caixinglobal.com | Hua Ang |Wang Xintong
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Drug researcher QuantumPharm Inc.
-
Jul 31, 2024 | 
caixinglobal.com | Hua Ang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
The Shanghai government has unveiled a plan to reform its biopharmaceutical industry policies in an effort to promote the local sector and bolster innovation.
The Opinions on Supporting the Whole Chain Innovation and Development of the Biopharmaceutical Industry were released at a press conference on Tuesday.
-
Jul 11, 2024 | 
caixinglobal.com | Hua Ang |Han Wei
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Chinese innovative drugmaker Sichuan Biokin Pharmaceutical Co. Ltd. has filed with the Hong Kong Stock Exchange for an initial public offering (IPO) in an effort to tap fresh funding to support new drug development and overseas expansion.
Biokin, already listed in Shanghai, did not disclose the target size of its Hong Kong offering.
-
Jun 14, 2024 | 
caixinglobal.com | Zhou Xinda |Hua Ang |Wang Xintong |Guo Xin
Explore the story in 3 minutesChina's domestic drug pricing policy has been a source of frustration for pharmaceutical companies over the past decade. Since 2016, the national insurance regulator has aggressively negotiated with companies to include innovative drugs in state health insurance to lower patient costs. This has hindered profits, pushing some companies to explore foreign markets for better margins.
-
Jun 14, 2024 | 
caixinglobal.com | Zhou Xinda |Hua Ang |Wang Xintong |Guo Xin
For nearly a decade, China’s domestic drug pricing policy has frustrated pharmaceutical companies.
Since 2016, the national insurance regulator has haggled with companies eager to have their innovative drugs covered by state health insurance, to help lower costs for patients.
This has made profits elusive for these companies. As a result, some have expanded into foreign markets in search of wider margins.
You've accessed an article available only to subscribers
-
Apr 9, 2024 | 
caixinglobal.com | Wang Xintong |Hua Ang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
What’s new: Some local governments across China, now including Beijing, have issued policies aimed at boosting the biopharmaceutical industry, including more financing support for innovative drugmakers, as the industry endures a prolonged capital winter.
-
Apr 5, 2024 | 
caixinglobal.com | Hua Ang |Lin Jinbing
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Danish biotech giant Genmab AS has agreed to acquire ProfoundBio Inc. for a hefty $1.8 billion, in another sign of foreign pharma’s growing interest in Chinese or Chinese-founded biotech firms.
